Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

CME/CE

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

This week, the Center on Health Equity and Access covers news related to AI integration, disparities in pediatric hospitalizations, new advancements presented at the 2024 CMS Health Equity Conference, and an expert discussion on the cardiovascular field. 

Health Equity and Access Weekly Roundup: June 1, 2024

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

A large US study showed population-based multigene testing might be a cost-effective way to identify women at risk for breast and ovarian cancer, potentially preventing more cases but raising concerns about generalizability and cost.

Multigene Testing Offers Cost-Effectiveness, Broader Approach to Breast Cancer Prevention

There are effective strategies that can be employed concurrently to promote adherence to medications for schizophrenia, including but not limited to pharmacological, technological, and psychosocial interventions. 

Contributor: Patient-Centered Approaches to Supporting Medication Adherence Among Persons With Schizophrenia

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Distinct retinal vessel atrophy patterns may be associated with multiple sclerosis (MS), but further research is needed to assess retinal vessel changes and their underlying role in MS.

Retinal Vasculature Pathology Linked With MS Disease Burden

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

ALL/AML

CLL/SLL

DLBCL

GVHD

Hemophilia

Leukemia and Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloprolioferative Neoplasms

Rare Blood

Hematology

Liver

Hepatology

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Immunology

COVID-19

Vaccines

Infectious Disease

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

Immuno-Oncology

Liver Cancer

Lung Cancer

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Soft Tissue Sarcoma

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Center on Health Equity & Access

Digital Health

Formulary

Gene Therapy

Guidelines

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Calcium Channel Blockers:  1995 - An Overview

Safety of Calcium Channel Blockers: Results of Recent Trials

Calcium Channel Blockers: New Trials and Trials in Progress

Are Calcium Channel Blockers Prohemorrhagic?

A Provocative Interpretation of the Case Control Analysis

Update - January 1996: FDA Does Not Support Labeling Changes to Calcium Antagonists Other Than Immediate-Release Nifedipine